Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foralumab MAD in Crohn's Disease
NCT05028946Phase 1Withdrawn
- Sponsor
- Tiziana Life Sciences
- Start
- May 2022
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of foralumab in Crohn's disease (4 cohorts), sponsored by Tiziana Life Sciences. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs). Planned start May 2022; status: withdrawn.
02
Drugs
foralumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05028946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028946.